This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Gold caught a breather from its latest plunge on Tuesday and offered participants at least some hope of a relief rally. The rationale for a gold summer rally was actually offered in microcosm on Tuesday’s trading session, as I’ll explain in today’s commentary. While the downward trend remains intact for the metal, once the latest wave of tariff-related weakness in the equity market has abated, gold should be able to finally experience at least a short-term turnaround.
RGLD GDX IAU RGL
Here's a monthly recap of the top news in the gold mining sector, including acquisitions and takeover announcements, financial results and other relevant updates, to keep readers up-to-date on news in the sector. Here's my update for May, in case you missed it.
AGCBF RIO RIO YRI KGI.DB CG CAGDF RTPPF FPC AUY OR RTNTF FPRGF SEMFF KL WPM SAND SSL SDDXF KGI OKSWF KGI.DB.A SNXZF RGLD AGC RIO OSKGF RGL
TORONTO, July 03, 2018 (GLOBE NEWSWIRE) -- Amarillo Gold Corporation (“Amarillo” or the “Company”) (TSX.V:AGC) is pleased to report that it has completed the previously-announced sale of a perpetual 1.75% Net Smelter Return Royalty (the “Royalty”) on the Mara Rosa gold project (the “Mara Rosa Project”) to RG Royalties, LLC, a wholly-owned subsidiary of Royal Gold, Inc. (NASDAQ:RGLD) (“Royal Gold”), for USD $10.
AGCBF RGLD AGC RGL
Editor’s note: Below, you’ll find the latest essay in Matt McCall’s series on how to make money during the coming marijuana boom. In this essay, Matt reveals what could turn out to be the ultimate way to invest in legal marijuana.
RGLD FNV.WT.A SLW FNV SLW FNV RGL
TORONTO, June 29, 2018 (GLOBE NEWSWIRE) -- Amarillo Gold Corporation (“Amarillo” or the “Company”) (TSX.V:AGC) today announces the entry into an agreement for sale of a perpetual 1.75% Net Smelter Return Royalty on the Mara Rosa gold project (the “Royalty Agreement”) to RG Royalties, LLC, a wholly-owned subsidiary of Royal Gold, Inc. (NASDAQ:RGLD) (“Royal Gold”), for USD $10.8 million (approximately CAD$14.
AGCBF RGLD AGC RGL
On Jun 28, we issued an updated research report on Royal Gold, Inc. (RGLD - Free Report) . The company is poised to gain from improved production and progress in ramping up of new mines, as well as its debt-reduction efforts. However, inadequate water supplies at Mount Milligan and volatile gold prices are expected to affect its results. Let’s illustrate these growth factors in detail. Royal Gold to Gain From New Mines Royal Gold expects to start initial production from Peñasquito Pyrite Leach in LaRonde Zone 5 later in calendar year 2018, followed by Cortez Crossroads’ production.
FTI.WI FMC RGLD GM.WS.A KMG GM.WS.B GM.WS.C GM GM.WSB PII MEOH RGL
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to RGLD / Royal Gold, Inc. on message board site Silicon Investor.
|Royal Gold Inc||RGLD: Royal Gold, Inc.|
|Royal Gold (RGLD)|
as of ET